TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Eledon Pharmaceuticals
Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting

Eledon Pharmaceuticals announced positive Phase 2 trial results for tegoprubart, a potential new immunosuppression treatment for kidney transplant patients, showing promising safety and efficacy with reduced side effects compared to tacrolimus.

Insights
ELDN   positive

Company presented promising clinical trial results demonstrating potential breakthrough in kidney transplant immunosuppression, with plans to advance to Phase 3 development and strong safety profile for tegoprubart